Erratum: Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer.
作者信息
Sheng Jin, Fang Wenfeng, Yu Juan, Chen Nan, Zhan Jianhua, Ma Yuxiang, Yang Yunpeng, Huang Yan, Zhao Hongyun, Zhang Li
出版信息
Sci Rep. 2016 Apr 13;6:23850. doi: 10.1038/srep23850.
Abstract
摘要
相似文献
1
Erratum: Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer.勘误：非小细胞肺癌中肿瘤细胞上程序性死亡配体-1的表达在化疗前后有所不同。
Sci Rep. 2016 Apr 13;6:23850. doi: 10.1038/srep23850.
2
Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.程序性死亡配体 1 和 2 在肺的多形性癌中高表达：肉瘤样区和癌性区的比较。
Eur J Cancer. 2015 Nov;51(17):2698-707. doi: 10.1016/j.ejca.2015.08.013. Epub 2015 Aug 29.
3
Survivin and Smac gene expressions but not livin are predictors of prognosis in non-small cell lung cancer patients treated with adjuvant chemotherapy following surgery.Survivin 和 Smac 基因的表达，但 livin 不是，可作为手术辅助化疗的非小细胞肺癌患者预后的预测因子。
Jpn J Clin Oncol. 2010 Apr;40(4):327-35. doi: 10.1093/jjco/hyp165. Epub 2010 Jan 7.
4
Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.抗程序性死亡-1 和抗程序性死亡配体 1 抗体在癌症治疗中的应用。
Expert Opin Biol Ther. 2013 Jun;13(6):847-61. doi: 10.1517/14712598.2013.770836. Epub 2013 Feb 19.
5
Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society.程序性死亡配体-1免疫组织化学——病理学家面临的新挑战：来自肺病理学会成员的观点
Arch Pathol Lab Med. 2016 Apr;140(4):341-4. doi: 10.5858/arpa.2015-0506-SA. Epub 2016 Jan 18.
6
Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.Apo2配体/肿瘤坏死因子相关凋亡诱导配体与化疗协同作用，抑制原位肺肿瘤生长并提高生存率。
Cancer Res. 2004 Jul 15;64(14):4900-5. doi: 10.1158/0008-5472.CAN-04-0408.
7
Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.靶向PD-1/PD-L1通路的化合物用于癌症免疫治疗的临床评估。
J Oncol Pharm Pract. 2015 Dec;21(6):451-67. doi: 10.1177/1078155214538087. Epub 2014 Jun 9.
8
The impact of induction chemotherapy on the dosimetric parameters of subsequent radiotherapy: an investigation of 30 consecutive patients with locally-advanced non-small cell lung cancer and modern radiation planning techniques.诱导化疗对后续放疗剂量学参数的影响：对30例连续的局部晚期非小细胞肺癌患者及现代放射治疗计划技术的研究。
Radiat Oncol. 2015 Jan 31;10:32. doi: 10.1186/s13014-015-0332-9.
9
Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors.新兴免疫疗法在非小细胞肺癌（NSCLC）治疗中的应用：免疫检查点抑制剂的作用
Am J Clin Oncol. 2015 Aug;38(4):422-30. doi: 10.1097/COC.0000000000000059.
10
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.阿特珠单抗对比多西他赛用于治疗既往接受过治疗的非小细胞肺癌患者（POPLAR）：一项多中心、开放标签、2 期随机对照临床试验。
Lancet. 2016 Apr 30;387(10030):1837-46. doi: 10.1016/S0140-6736(16)00587-0. Epub 2016 Mar 10.
引用本文的文献
1
Novel Composite Scoring System for Predicting Prognosis in Stage IV Gastric Cancer Patients Treated with Immune Checkpoint Inhibitors.用于预测接受免疫检查点抑制剂治疗的IV期胃癌患者预后的新型综合评分系统
J Inflamm Res. 2025 May 22;18:6491-6504. doi: 10.2147/JIR.S519724. eCollection 2025.
2
PD-L1 expression testing in non-small cell lung cancer.非小细胞肺癌中的程序性死亡受体配体1（PD-L1）表达检测
Ther Adv Med Oncol. 2018 Apr 11;10:1758835918763493. doi: 10.1177/1758835918763493. eCollection 2018.
3
Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma.恶性胸膜间皮瘤中肿瘤免疫微环境和免疫检查点的预后及预测方面
Oncoimmunology. 2016 Nov 28;6(1):e1261241. doi: 10.1080/2162402X.2016.1261241. eCollection 2017.
Zotero 插件